US-Based Startup PerZeption Partners with Alcon for Vision Technology Advancements

On May 1, 2026, Boston-based PerZeption Inc. announced a groundbreaking collaboration with Alcon, a major player in the ophthalmology field. The partnership aims to further enhance methods of evaluating vision correction, emphasizing precision and efficiency in detecting clinically significant visual differences.

During the upcoming Association of Research in Vision and Ophthalmology (ARVO) annual meeting, PerZeption will unveil new findings regarding its AIM+ CSF modeling technology. These findings will be presented during a poster session scheduled for May 4, 2026, where attendees will have the chance to explore the innovative approach at posterboard #0941.

Dr. Jan Skerswetat, a key figure at PerZeption, expressed excitement about the collaboration, stating, "We are very excited to collaborate with Alcon, one of the largest companies within the Ophthalmology sector worldwide." He further added that the results shared by Dr. Derek Nankivil demonstrate that their technology is capable of providing fast, repeatable, and highly sensitive assessments of contrast vision.

The research details, encapsulated in an abstract titled 'AIM+ CSF modeling enables efficient detection of clinically meaningful visual differences,' illustrate how PerZeption's approach aids in sensitive and low-burden visual evaluation. Specifically, studies suggest that by utilizing just six adaptive display stimuli and two repetitions, researchers can achieve 90% power to detect a 1 Just Noticeable Difference (JND) change in AULCSF (Area Under the Log Contrast Sensitivity Function) with a group of about 20 subjects.

Additionally, the research showcases the AIM+ CSF technology's reliable repeatability, capable of delivering results in under three minutes. The absence of bias and strong performance underscore its potential as a valuable tool for objective visual performance assessment.

This collaboration signifies a mutual commitment to pushing forward ophthalmology research and improving the tools available for visual assessments. The ARVO annual meeting stands as a pivotal event for ophthalmology research, fostering an environment for the exchange of scientific discoveries and dialogue within the global vision science community.

Dr. Skerswetat also mentioned that PerZeption will showcase a variety of functional tests at their booth (#4027) during the ARVO meeting, encouraging attendees to engage with their technology firsthand.

PerZeption, recognized for its rapid, self-administered, and adaptive vision testing platform delivered through cloud-based software, is transforming the landscape of vision testing. Their flagship platform, Angular Indication Measurement (AIM), facilitates the assessment of over 20 visual functions. This novel methodology equips researchers and clinicians with an extensive array of visual function tests, many of which are unavailable through existing devices.

By minimizing the time patients spend in the testing chair and providing self-administered tests on a single device, PerZeption significantly reduces user burden. Their innovative use of proprietary methods enables swift vision assessments while requiring minimal training or space, in stark contrast to traditional bulky, specialized devices. The cloud-based delivery system also guarantees consistent and secure results, marking a critical evolution in in-clinic and remote testing for both clinicians and pharmaceutical firms.

In summary, the partnership between PerZeption and Alcon through the validation of AIM+ CSF technology serves as a promising development in the field of ophthalmology, highlighting the importance of accurate and efficient vision assessment tools. As these advancements emerge, the collaboration exemplifies the continued innovation in visual science aimed at enhancing patient care and clinical practices.